Monitoring anti-TNF  treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage

Haavardsholm, Espen A; Østergaard, Mikkel; Hammer, Hilde Berner; Bøyesen, Pernille; Boonen, A.; Heijde, D. van der; Kvien, Tore K

doi:10.1136/ard.2008.091801

Cited by 89 publications

(69 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RAMRIS is being used increasingly in trials of biological agents to measure changes in these markers for disease activities. Recent work has shown that in the cohort of patients receiving tumor necrosis factor alpha (TNFα) treatment, the MR total inflammation score displayed superior responsiveness to conventional measures of disease activity, indicating its promise as an outcome measure in clinical studies and for clinical practice [23].…”

Section: The Outcome Measures In Rheumatoid Arthritis Clinical Trialsmentioning

confidence: 99%

Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger

et al. 2010

View full text Add to dashboard Cite

Section: The Outcome Measures In Rheumatoid Arthritis Clinical Trialsmentioning

confidence: 99%

Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger

et al. 2010

View full text Add to dashboard Cite

“…Moreover, a wide variability was identified regarding the therapy assumed by the enrolled patients (etanercept, adalimumab, infliximab) and the follow-up, ranging from 12 weeks and 24 months. The number of joints evaluated was variable: some studies included a single joint (wrist) [75], other studies evaluated a great number of articular sites (78 joints assessed in the study conducted by Hammer et al in 2010) [77]. All studies demonstrated a significant reduction of US score after treatment with TNF-antagonist, irrespective of the follow-up.…”

Section: Main Applicationsmentioning

confidence: 99%

“…First, Hau and colleagues observed a significant reduction of the numbers of Doppler signals at MCP level in 5 RA patients [71]. From 2005, when OMERACT definitions were published, 12 studies evaluated the efficacy of anti-TNF drugs by using US assessment [11,16,17,21,24,25,[72][73][74][75][76][77]. The number of patients enrolled in the studies was variable, ranging from 18 to 278 patients.…”

Section: Main Applicationsmentioning

confidence: 99%

Ultrasound in Rheumatoid Arthritis

et al. 2013

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation that can lead to structural damage of cartilage, bone and tendons. Assessing the inflammatory activity and the severity is essential in RA to help rheumatologists in adopting proper therapeutic strategies and in evaluating disease outcome and response to treatment. In the last years musculoskeletal (MS) ultrasonography (US) underwent tremendous technological development of equipment with increased sensitivity in detecting a wide set of joint and soft tissues abnormalities. In RA MSUS with the use of Doppler modalities is a useful imaging tool to depict inflammatory abnormalities (i.e. synovitis, tenosynovitis and bursitis) and structural changes (i.e. bone erosions, cartilage damage and tendon lesions). In addition, MSUS has been demonstrated to be able to monitor the response to different therapies in RA to guide local diagnostic and therapeutic procedures such as biopsy, fluid aspirations and injections. Future applications based on the development of new tools may improve the role of MSUS in RA.

show abstract

“…Erosions, bone edema, and synovitis depicted by MRI have been shown to cover all aspects of truth 12,13,14,15,16,17 , and the RA MRI score (RAMRIS) for erosions, bone edema, and synovitis has also demonstrated responsiveness and discrimination 18,19,20,21,22 . Although feasibility issues such as accessibility, time, cost, and patient compliance may cause limitations in clinical practice, MRI is acceptable for clinical trials.…”

Section: Imaging and Soluble Biomarkers In Ramentioning

confidence: 99%

Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers

D'Agostino

Boers²,

Kirwan³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for the validation of outcome measures for use in rheumatology clinical research. However, imaging and biochemical measures may face additional validation challenges because of their technical nature. The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the iterative development of an imaging or biochemical measurement instrument so it can be used in therapeutic assessment. Methods. A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an imaging or biochemical measurement instrument: outcome domain(s), study setting, and performance of the instrument. Movement along the axes in any dimension reflects increasing validation. For a given test instrument, the 3-axis structure assesses the extent to which the instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or disease-centered variable, and whether its technical performance is adequate in the context of its application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondy-loarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the newly proposed structure. Breakout groups critically reviewed the extent to which the candidate biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the proposed 3-dimensional structure. Results. Although there was a broad acceptance of the value of the proposed structure in general, some areas for improvement were suggested including clarification of criteria for achieving a certain level of validation and how to deal with extension of the structure to areas beyond clinical trials. Conclusion. General support was obtained for a proposed tri-axis structure to assess validation of imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place within the OMERACT Filter 2.0

show abstract

Monitoring anti-TNF treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage

Abstract: The most responsive measure of inflammation when evaluating anti-TNFalpha medication was a composite measure comprising MRI synovitis, tenosynovitis and bone marrow oedema, and this may be a promising outcome measure in clinical studies.

Cited by 89 publications

References 46 publications

Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger

Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger

Ultrasound in Rheumatoid Arthritis

Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers

Contact Info

Product

Resources

About